218 related articles for article (PubMed ID: 30478785)
41. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
42. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
43. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
Jansen MP; Ruigrok-Ritstier K; Dorssers LC; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Helleman J; Sleijfer S; Klijn JG; Foekens JA; Berns EM
Breast Cancer Res Treat; 2009 Jul; 116(2):263-71. PubMed ID: 18629630
[TBL] [Abstract][Full Text] [Related]
44. Assessment of hormone receptor status in breast cancer.
Horii R; Akiyama F; Ito Y; Iwase T
Pathol Int; 2007 Dec; 57(12):784-90. PubMed ID: 17988279
[TBL] [Abstract][Full Text] [Related]
45. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
46. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.
Witkiewicz AK; Dasgupta A; Sotgia F; Mercier I; Pestell RG; Sabel M; Kleer CG; Brody JR; Lisanti MP
Am J Pathol; 2009 Jun; 174(6):2023-34. PubMed ID: 19411448
[TBL] [Abstract][Full Text] [Related]
47. Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer.
Reimer T; Koczan D; Müller H; Friese K; Thiesen HJ; Gerber B
Breast Cancer Res; 2002; 4(5):R9. PubMed ID: 12223126
[TBL] [Abstract][Full Text] [Related]
48. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
49. [Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].
Zhang J; Zhang JH; Liu Y; Hao XM; Fang ZX; Li SL
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(46):3268-71. PubMed ID: 18396622
[TBL] [Abstract][Full Text] [Related]
50. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
[TBL] [Abstract][Full Text] [Related]
51. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
[TBL] [Abstract][Full Text] [Related]
52. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
53. Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines.
Trošt N; Hevir N; Rižner TL; Debeljak N
Int J Mol Med; 2013 Mar; 31(3):717-25. PubMed ID: 23314808
[TBL] [Abstract][Full Text] [Related]
54. Quantitative progesterone receptor expression and efficacy of anti-estrogen therapy in breast cancer.
Luoh SW; Ramsey B; Park B; Keenan E
Breast J; 2014; 20(1):46-52. PubMed ID: 24261828
[TBL] [Abstract][Full Text] [Related]
55. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology).
Inal A; Akman T; Yaman S; Demir Ozturk S; Geredeli C; Bilici M; Inanc M; Harputoglu H; Demirci U; Balakan O; Yesil Cinkir H; Alici S; Uysal Sonmez O; Goksel G; Gokoz Dogu G; Umit Unal O; Tamozlu T; Buyukberber S; Melih Boruban C; Isikdogan A
J BUON; 2013; 18(1):64-9. PubMed ID: 23613390
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
57. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
Generali D; Fox SB; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield SM; Bruzzi P; Bersiga A; Allevi G; Milani M; Aguggini S; Dogliotti L; Bottini A; Harris AL
Endocr Relat Cancer; 2006 Sep; 13(3):921-30. PubMed ID: 16954440
[TBL] [Abstract][Full Text] [Related]
58. Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.
Lykkesfeldt AE; Iversen BR; Jensen MB; Ejlertsen B; Giobbie-Hurder A; Reiter BE; Kirkegaard T; Rasmussen BB
Acta Oncol; 2018 Jan; 57(1):67-73. PubMed ID: 29202611
[TBL] [Abstract][Full Text] [Related]
59. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan VC; Brodie AM
Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
[TBL] [Abstract][Full Text] [Related]
60. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
Veronesi U; Maisonneuve P; Rotmensz N; Costa A; Sacchini V; Travaglini R; D'Aiuto G; Lovison F; Gucciardo G; Muraca MG; Pizzichetta MA; Conforti S; Decensi A; Robertson C; Boyle P;
J Natl Cancer Inst; 2003 Jan; 95(2):160-5. PubMed ID: 12529349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
